← All trials
NCT03043313
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 23, 2017
- Primary completion
- Jun 30, 2019
- Completion date
- Jun 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 35
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Academic and Community Cancer Research UnitedLead sponsor
- Duke UniversityStudy chair
- National Cancer Institute (NCI)Collaborator
- Cascadian Therapeutics Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.